ID: ALA3288362

Max Phase: Preclinical

Molecular Formula: C19H22O4

Molecular Weight: 314.38

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCOC(CC(=O)O)c1ccc(OCc2ccccc2C)cc1

Standard InChI:  InChI=1S/C19H22O4/c1-3-22-18(12-19(20)21)15-8-10-17(11-9-15)23-13-16-7-5-4-6-14(16)2/h4-11,18H,3,12-13H2,1-2H3,(H,20,21)

Standard InChI Key:  WQMYKBGTTBVBQN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 314.38

Molecular Weight (Monoisotopic): 314.1518

AlogP: 4.13

#Rotatable Bonds: 8

Polar Surface Area: 55.76

Molecular Species: ACID

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 4.13

CX Basic pKa:

CX LogP: 4.06

CX LogD: 0.98

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.80

Np Likeness Score: -0.36

References

1. Takano R, Yoshida M, Inoue M, Honda T, Nakashima R, Matsumoto K, Yano T, Ogata T, Watanabe N, Toda N..  (2014)  Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.,  24  (13): [PMID:24835985] [10.1016/j.bmcl.2014.04.065]

2. Takano R, Yoshida M, Inoue M, Honda T, Nakashima R, Matsumoto K, Yano T, Ogata T, Watanabe N, Hirouchi M, Yoneyama T, Ito S, Toda N..  (2015)  Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.,  6  (3): [PMID:25815144] [10.1021/ml500391n]

3. Takano R, Yoshida M, Inoue M, Honda T, Nakashima R, Matsumoto K, Yano T, Ogata T, Watanabe N, Hirouchi M, Kimura T, Toda N..  (2015)  Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558.,  23  (17): [PMID:26234904] [10.1016/j.bmc.2015.07.028]

Source

Source(1):

• Scientific Literature